SwanBio Therapeutics

What SwanBio Therapeutics does

SwanBio Therapeutics, now operating as Spur Therapeutics following a 2024 rebrand, is a clinical-stage biotech developing AAV-based gene therapies for rare neurological and genetic diseases, with a stated strategy to expand into more prevalent conditions. The company's lead candidate SBT101 is an AAV gene therapy designed to deliver a functional copy of the ABCD1 gene to treat adrenomyeloneuropathy (AMN), currently being evaluated in the first-in-human PROPEL Phase 1/2 trial, which has progressed to its second dose-escalation cohort and expanded into Europe following EU regulatory approval. A second core program, avigbagene parvec (FLT201), targets Gaucher disease type 1 and is being evaluated in the ongoing GALILEO-3 Phase 3 registrational trial, with two-year follow-up data from prior GALILEO-1 and GALILEO-2 trials supporting the program. The pipeline is publicly broadening into Parkinson's disease, dementia, and cardiovascular indications.

The company operates a pre-revenue, clinical-development business model with no commercialized products; expected future revenue is premised on one-time gene therapy product sales at premium rare-disease pricing upon regulatory approval, distributed through specialized rare-disease treatment centers and academic medical centers. Go-to-market motion is event-driven, anchored to clinical trial milestones, DSMB reviews, and regulatory approvals rather than traditional sales execution. SwanBio/Spur is privately held and headquartered in the United States with an operating footprint across the U.S. and Europe; it is majority-owned by Syncona Limited, which has committed approximately $64 million across a $56M Series B (May 2022) and a $10M follow-on (October 2023). The company conducted a ~25% workforce reduction in 2022 ahead of the Series B, indicating a lean operational posture relative to its clinical ambitions.

Name

SwanBio Therapeutics

Legal name

Spur Therapeutics

Website

https://swanbiotx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

SwanBio Therapeutics (now Spur Therapeutics) is a clinical-stage biotech developing AAV-based gene therapies for rare neurological and genetic diseases, with lead candidates SBT101 for adrenomyeloneuropathy and avigbagene parvec for Gaucher disease type 1.

Ownership category

akta.pro rank

Product category

Gene Therapy Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Gene therapy development
• AAV gene therapies
• Rare disease therapeutics
• Clinical-stage biotechnology
• Neurological disease treatments

Headquarters

HQ city

Bala Cynwyd

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Gene Therapy Product Sales: Pre-revenue clinical-stage company. Expected revenue model is one-time gene therapy treatment sales upon regulatory approval and commercialization. Gene therapies typically command premium pricing as single-dose treatments that potentially modify or halt disease progression.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

SwanBio Therapeutics (now operating as Spur Therapeutics) is a clinical-stage biotechnology company developing AAV-based gene therapies for rare neurological and genetic diseases. Its lead candidates include SBT101 for adrenomyeloneuropathy (AMN) in Phase 1/2 (PROPEL trial) and avigbagene parvec (FLT201) for Gaucher disease type 1 in a Phase 3 registrational trial (GALILEO-3). The pipeline is expanding into Parkinson's disease, dementia, and cardiovascular indications.

Product overview

SwanBio Therapeutics (now operating as Spur Therapeutics) is a clinical-stage biotech developing gene therapies for neurological and rare diseases. The company's lead product SBT101 is a gene therapy for adren myeloneuropathy (AMN) in Phase 1/2 trials (PROPEL). Another key product is avigbagene parvec (FLT201) for Gaucher disease type 1, currently in Phase 3 (GALILEO-3) with completed GALILEO-1 and GALILEO-2 trials. The pipeline includes programs targeting Parkinson's disease and other neurological conditions. The company leverages AAV gene therapy technology to deliver genetic medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• SBT101 AAV gene therapy candidate designed to deliver a functional copy of the ABCD1 gene to address the underlying genetic cause of adrenomyeloneuropathy (AMN), a rare X-linked metabolic disorder affecting the nervous system. Currently being evaluated in the PROPEL Phase 1/2 clinical trial.
• Avigbagene parvec (FLT201) AAV gene therapy candidate for adults with Gaucher disease type 1, a rare genetic lysosomal storage disorder. Being evaluated in GALILEO-3 Phase 3 registrational trial with prior Phase 1/2 trials demonstrating sustained efficacy.
• Gene Therapy Pipeline for Parkinson's Disease

Quantifiable outcome

• DSMB recommended dose escalation based on positive safety data from first cohort
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Regulatory Authorities (EU)coreOthersEuropean regulatory authorities granted approval enabling the expansion of the PROPEL clinical trial into Europe. This partnership involves regulatory submission and approval processes required to conduct clinical trials across multiple countries in Europe.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• uniQure: uniQure is a clinical-stage gene therapy company developing AAV-based therapies for rare and CNS diseases, including hemophilia B and Huntington's disease. It is a direct peer to Spur Therapeutics given shared AAV platform, rare neurological disease focus, and similar clinical-stage profile.
• Regenxbio: Regenxbio is a leading AAV gene therapy technology platform company with internal and partnered programs across ophthalmology, CNS, and metabolic diseases. It is highly comparable to Spur as both develop optimized AAV vectors for rare and neurological indications, and Regenxbio's NAV technology underpins many industry AAV programs.
• Voyager Therapeutics: Voyager Therapeutics develops AAV-based gene therapies for severe neurological diseases including Parkinson's disease, Huntington's disease, and ALS. It is a direct peer due to overlapping AAV capsid engineering focus and shared CNS/neurological disease pipeline, including Parkinson's where both companies compete.
• bluebird bio: bluebird bio is a gene therapy company developing lentiviral and AAV-based therapies for severe genetic diseases including cerebral adrenoleukodystrophy (CALD), sickle cell disease, and beta-thalassemia. It is a direct peer given shared rare monogenic disease focus and gene therapy modality, and notably targets ABCD1-related disease (CALD) adjacent to Spur's AMN program.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with marketed products (e.g., Roctavian for hemophilia A) and a deep pipeline of AAV gene therapies. It is a broad incumbent that competes with Spur in the rare-disease AAV gene therapy space and has greater commercial scale and capital resources.
• Pfizer: Pfizer is a multinational pharmaceutical company with an active gene therapy franchise (e.g., Beqvez for hemophilia B and inherited metabolic disease programs via the Spark Therapeutics acquisition). It is a broad incumbent that operates a parallel AAV gene therapy strategy targeting rare monogenic diseases overlapping with Spur's portfolio.
• Novartis: Novartis commercializes Zolgensma, the landmark AAV gene therapy for spinal muscular atrophy, and continues to invest in AAV gene therapy for CNS and metabolic indications. It is a broad incumbent in the AAV gene therapy space with established manufacturing, regulatory, and commercial infrastructure relevant to Spur's commercialization path.
• Prevail Therapeutics (Eli Lilly): Prevail Therapeutics, acquired by Eli Lilly, develops AAV gene therapies for neurodegenerative diseases including Parkinson's disease and frontotemporal dementia. It is a broad incumbent comparable to Spur in the CNS AAV gene therapy space, particularly relevant to Spur's Parkinson's disease pipeline ambition.
• Spark Therapeutics (Roche): Spark Therapeutics, a Roche subsidiary, developed and commercializes Luxturna, the first FDA-approved AAV gene therapy, and is developing AAV gene therapies for hemophilia and other rare diseases. It is a broad incumbent directly comparable to Spur on AAV modality, rare disease focus, and regulatory path.

Emerging players

• Taysha Gene Therapies: Taysha Gene Therapies is a clinical-stage AAV gene therapy company focused on severe monogenic CNS diseases including Rett syndrome and GAN. It is an emerging peer given its smaller scale, AAV platform focus, and CNS rare-disease pipeline comparable to Spur's lead programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/swanbio-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SwanBio Therapeutics